Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02049593
Recruitment Status : Active, not recruiting
First Posted : January 30, 2014
Last Update Posted : July 18, 2018
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center

Brief Summary:
This phase I trial studies the side effects and the best dose of poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor BMN-673 when given together with temozolomide or irinotecan hydrochloride in treating patients with locally advanced or metastatic solid tumors. PARP inhibitor BMN-673 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help temozolomide and irinotecan hydrochloride work better by making tumor cells more sensitive to the drug. Drugs used in chemotherapy, such as temozolomide and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving PARP inhibitor BMN-673 with temozolomide or irinotecan hydrochloride may be an effective treatment for patients with advanced solid tumors.

Condition or disease Intervention/treatment Phase
Metastatic Cancer Unspecified Adult Solid Tumor Drug: PARP inhibitor BMN-673 Drug: temozolomide Drug: irinotecan hydrochloride Other: pharmacological study Other: laboratory biomarker analysis Phase 1

Detailed Description:

PRIMARY OBJECTIVES:

I. To assess the safety and tolerability and to estimate the maximum tolerated dose (MTD) of the following combinations in participants with advanced solid tumors: Arm A: BMN 673 (PARP inhibitor BMN-673) and temozolomide; Arm B: BMN 673 and irinotecan (irinotecan hydrochloride).

SECONDARY OBJECTIVES:

I. To evaluate the pharmacokinetics of BMN 673, temozolomide, and irinotecan when BMN 673 is given in combination with temozolomide (Arm A) or irinotecan (Arm B). To assess the effects of temozolomide and irinotecan in Arms A and B respectively on the pharmacokinetics of BMN 673.

II. To evaluate biomarkers that correlate with effect of BMN 673 in combination with temozolomide or irinotecan.

III. To document any anti-tumor activity.

OUTLINE: This is a dose-escalation study of PARP inhibitor BMN-673. Patients are assigned to 1 of 2 treatment arms.

ARM A: Patients receive PARP inhibitor BMN-673 orally (PO) once daily (QD) on days 1-28 and temozolomide PO daily on days1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

ARM B: Patients receive PARP inhibitor BNM-673 as in Arm A and irinotecan hydrochloride intravenously (IV) on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for up to 12 months.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 41 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Trial of BMN 673 and Selected Cytotoxics in Patients With Advanced Solid Tumors
Actual Study Start Date : June 12, 2014
Estimated Primary Completion Date : June 30, 2019
Estimated Study Completion Date : June 30, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Arm A (PARP inhibitor BMN-673, temozolomide)
Patients receive PARP inhibitor BMN-673 PO QD on days 1-28 and temozolomide PO daily on days1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: PARP inhibitor BMN-673
Given PO
Other Names:
  • BMN 673
  • BMN-673

Drug: temozolomide
Given PO
Other Names:
  • SCH 52365
  • Temodal
  • Temodar
  • TMZ

Other: pharmacological study
Correlative studies
Other Name: pharmacological studies

Other: laboratory biomarker analysis
Correlative studies

Experimental: Arm B (PARP inhibitor BMN-673, irinotecan hydrochloride)
Patients receive PARP inhibitor BNM-673 as in Arm A and irinotecan hydrochloride IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: PARP inhibitor BMN-673
Given PO
Other Names:
  • BMN 673
  • BMN-673

Drug: irinotecan hydrochloride
Given IV
Other Names:
  • Campto
  • Camptosar
  • CPT-11
  • irinotecan
  • U-101440E

Other: pharmacological study
Correlative studies
Other Name: pharmacological studies

Other: laboratory biomarker analysis
Correlative studies




Primary Outcome Measures :
  1. Dose Limiting Toxicity graded using the NCI CTCAE v. 4.03 [ Time Frame: Up to 28 days ]

Secondary Outcome Measures :
  1. Incidence of adverse events graded by NCI CTCAE v. 4.03 [ Time Frame: Up to 12 months ]
    Characterized by type, frequency, severity, timing, seriousness, and relationship to study therapy.

  2. Levels of PARP inhibitory BMN 673 [ Time Frame: Baseline, at 30 and 60 minutes, at 1.5, 2, 3, 4, 6, and 8 hours of day 1 of courses 1 and 2 ]
  3. levels of temozolomide [ Time Frame: Baseline, at 30 and 60 minutes, at 1.5, 2, 3, 4, 6, and 8 hours of day 1 of courses 1 and 2 ]
  4. Levels of irinotecan hydrochloride [ Time Frame: Baseline, at 30 and 60 minutes, at 1.5, 2, 3, 4, 6, and 8 hours of day 1 of courses 1 and 2 ]
  5. Biomarker levels in blood and tumor tissue [ Time Frame: Baseline and Cycle1 Day 21 for participants undergoing biopsy (expansion phase only) ]
  6. Incidence of laboratory abnormalities graded by NCI CTCAE v. 4.03 [ Time Frame: Up to 12 months ]
    Characterized by type, frequency, severity, timing, seriousness and relationship to study therapy.

  7. Objective tumor response assessed using RECIST v. 1.1 [ Time Frame: Up to 12 months ]
    Sum of partial responses plus complete responses. The proportion of ever achieving a clinical response will be estimated, and an exact one-sided 90% confidence interval will be constructed to identify the likely range for the underlying tumor response rate.

  8. Duration of response [ Time Frame: Time of initial response until documented tumor progression, assessed up to 12 months ]
    The log rank test will be used to examine association between categorical markers and time to disease progression. Cox-proportional hazards regression models will be used to correlate quantitative markers with time to disease progression.

  9. Progression-free survival [ Time Frame: Time from enrollment until objective tumor progression or death, assessed up to 12 months ]
  10. Overall survival (OS) [ Time Frame: Time from randomization until death from any cause, up to 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically documented, unresectable, locally advanced or metastatic solid tumor for which no standard therapy is recognized or for which standard therapy has failed
  • Measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST, v1.1)
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN); if liver function abnormalities are due to hepatic metastasis, then AST and ALT may be =< 5 x ULN
  • Total serum bilirubin =< 1.5 x ULN
  • Calculated creatinine clearance of >= 40 ml/min; as per Cockcroft-Gault formula
  • Hemoglobin >= 9.0 g/dL
  • Absolute neutrophil count (ANC) >= 1500/mm^3
  • Platelet count >= 100,000/mm^3
  • Able to take oral medications
  • Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures
  • Sexually active patients must be willing to use an acceptable method of contraception such as double barrier contraception during treatment and for 30 days after the last dose of BMN 673
  • Females of childbearing potential must have a negative serum pregnancy test at screening

Exclusion Criteria:

  • Has not recovered (recovery is defined as National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE version (v)4.03] grade =< 1) from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting the inclusion requirements stated in the inclusion criterion
  • Prior treatment with a PARP inhibitor
  • Prior allergic reaction or severe intolerance to either irinotecan or temozolomide
  • History of central nervous system (CNS) metastasis that are untreated or not stable
  • Any antitumor systemic cytotoxic therapies within 28 days prior to enrollment (6 weeks for nitrosoureas or mitomycin-C); prior high-dose chemotherapy with bone marrow or stem cell transplant is excluded
  • Is known to have human immunodeficiency virus (HIV) or has active hepatitis C virus (HCV), or active hepatitis B virus (HBV)
  • Has had major surgery within 28 days prior to enrollment
  • Active gastrointestinal tract disease with malabsorption syndrome
  • Requirement for IV alimentation
  • Uncontrolled inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
  • Symptomatic congestive heart failure (New York Heart Association > class II), unstable angina, or unstable cardiac arrhythmia requiring medication (atrial fibrillation is permitted)
  • Use of any investigational product or investigational medical device within 28 days prior to enrollment
  • Concurrent disease or condition that would interfere with study participation or safety, such as:

    • Active, clinically significant infection requiring the use of parenteral anti-microbial agents, or grade > 2 by NCI CTCAE (v 4.03) within 14 days prior to enrollment
    • Clinically significant bleeding diathesis or coagulopathy, including known platelet function disorders
    • Non-healing wound, ulcer, or bone fracture
    • Bone marrow disorder including myelodysplasia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02049593


Locations
Layout table for location information
United States, California
Jonsson Comprehensive Cancer Center
Los Angeles, California, United States, 90095
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Zev Wainberg Jonsson Comprehensive Cancer Center

Layout table for additonal information
Responsible Party: Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT02049593     History of Changes
Other Study ID Numbers: TRIO-US GI-07
NCI-2014-00048 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
TRIO-US GI-07 ( Other Identifier: Jonsson Comprehensive Cancer Center )
P30CA016042 ( U.S. NIH Grant/Contract )
First Posted: January 30, 2014    Key Record Dates
Last Update Posted: July 18, 2018
Last Verified: June 2018

Keywords provided by Jonsson Comprehensive Cancer Center:
protocol specific

Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplastic Processes
Neoplasms
Pathologic Processes
Irinotecan
Temozolomide
Talazoparib
Poly(ADP-ribose) Polymerase Inhibitors
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents